ArticleActa diabetologica2026
GLP-1 receptor agonist use and contrast-associated acute kidney injury after contrast-enhanced CT and CT angiography in adults with type 2 diabetes and chronic kidney disease: a propensity score-matched cohort study.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo examine whether glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with contrast-associated acute kidney injury (CA-AKI) after contrast-enhanced computed tomography (CE-CT) or computed tomographic angiography (CTA) in adults with type 2 diabetes and chronic kidney disease (CKD).
methodsWe conducted a TriNetX retrospective cohort study of adults with type 2 diabetes and CKD who underwent CE-CT or CTA from January 2020 to January 2025. GLP-1 RA use was defined by a prescription within six months before imaging. The primary outcome was a new acute kidney injury diagnosis within three days. Separate 1:1 propensity score-matched analyses were conducted for CE-CT and CTA, with eGFR-stratified and sensitivity analyses.
resultsAfter matching, the CE-CT and CTA cohorts included 6,995 and 3,285 pairs, respectively. CA-AKI occurred in 3.8% of GLP-1 RA users versus 4.5% of non-users after CE-CT (odds ratio [OR] 0.84, 95% confidence interval [CI] 0.71-0.99) and in 4.5% versus 6.1% after CTA (OR 0.74, 95% CI 0.59-0.92). The absolute risk differences were 0.7% points and 1.5% points, respectively. HbA1c remained imbalanced after matching. Negative-control outcomes were null, and eGFR-stratified associations were inconsistent between cohorts.
conclusionsGLP-1 RA use was associated with a lower observed risk of CA-AKI after CE-CT and CTA in adults with type 2 diabetes and CKD. Residual HbA1c imbalance and the observational design limit causal interpretation; prospective studies using creatinine-based outcomes are needed.
Indexed as
Identifiers
42886239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.